Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.
Di Federico A, Angelicola S, Frascino M, Siracusa I, Bisanti B, Ruzzi F, Semprini MS, De Jonge H, De Giglio A, Sperandi F, Brocchi S, Melotti B, Giunchi F, Gruppioni E, Altimari A, Lollini PL, Ardizzoni A, Palladini A, Gelsomino F. Di Federico A, et al. Among authors: giunchi f. JCO Precis Oncol. 2024 Dec;8:e2400240. doi: 10.1200/PO.24.00240. Epub 2024 Dec 5. JCO Precis Oncol. 2024. PMID: 39637338 Free PMC article.
Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E, Dall'Olio FG, Gruppioni E, Sperandi F, Altimari A, Giunchi F, Fiorentino M, Ardizzoni A. Capizzi E, et al. Among authors: giunchi f. Lung Cancer. 2019 Sep;135:88-91. doi: 10.1016/j.lungcan.2019.07.017. Epub 2019 Jul 17. Lung Cancer. 2019. PMID: 31447007
Role of PD-L1 assessment in advanced NSCLC: does it still matter?
Rizzo A, Dall'Olio FG, Altimari A, Giunchi F, Ardizzoni A. Rizzo A, et al. Among authors: giunchi f. Anticancer Drugs. 2021 Nov 1;32(10):1084-1085. doi: 10.1097/CAD.0000000000001118. Anticancer Drugs. 2021. PMID: 34232942 No abstract available.
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini MS, Scalambra L, Altimari A, Gruppioni E, Fiorentino M, Giunchi F, Ferracin M, Astolfi A, Indio V, Ardizzoni A, Gelsomino F, Nanni P, Lollini PL, Palladini A. Ruzzi F, et al. Among authors: giunchi f. Transl Lung Cancer Res. 2022 Nov;11(11):2216-2229. doi: 10.21037/tlcr-22-163. Transl Lung Cancer Res. 2022. PMID: 36519016 Free PMC article.
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G. Fiorentino M, et al. Among authors: giunchi f. Oncotarget. 2017 Jan 31;8(5):7328-7335. doi: 10.18632/oncotarget.12551. Oncotarget. 2017. PMID: 27741505 Free PMC article.
Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers.
Giunchi F, Massari F, Altimari A, Gruppioni E, Nobili E, Fiorentino M, Ardizzoni A. Giunchi F, et al. Diagnostics (Basel). 2020 Dec 20;10(12):1109. doi: 10.3390/diagnostics10121109. Diagnostics (Basel). 2020. PMID: 33419298 Free PMC article.
116 results